ライフサイエンスコーパス: plasminogen activator

1 thrombolytic treatment with tPA (tissue-type plasminogen activator).

2 lular adhesion molecule-1 and urokinase-type plasminogen activator.

3 rrelated significantly with levels of tissue plasminogen activator.

4 ecreting enzymatic factors, including tissue plasminogen activator.

5 rotease plasmin by staphylokinase and tissue plasminogen activator.

6 ke was strictly dependent on plasminogen and plasminogen activator.

7 bolytic and proteolytic properties of tissue plasminogen activator.

8 pecific protein ligands, such as tissue-type plasminogen activator.

9 phaFXIIa is a highly efficient and favorable plasminogen activator.

10 marginal compared with urokinase and tissue plasminogen activator.

11 ukemia inhibitory factor, and urokinase-type plasminogen activator.

12 ptase and subsequent activation of urokinase plasminogen activator.

13 ular endothelial growth factor and urokinase plasminogen activator.

14 ation with phorbol esters and urokinase-type plasminogen activator.

15 vated alpha(2)-macroglobulin and tissue-type plasminogen activator.

16 intermediate phenotype in response to tissue plasminogen activator.

17 ction of blood mediates resistance to tissue plasminogen activator.

18 the aminoterminal fragment of urokinase-type plasminogen activator.

19 rt plasminogen to plasmin in the presence of plasminogen activators.

20 ibitor of the tissue type and urokinase type plasminogen activators.

21 is, increased tissue-type and urokinase-type plasminogen activators, a relatively decreased plasminog

22 derately reduced single-chain urokinase-type plasminogen activator activation.

23 The plasminogen activator activity of the alphaFXIIa-polyP70

24 for mouse plasma that is sensitive to tissue plasminogen activator, alpha2-antiplasmin, active plasmi

25 Intravenous recombinant tissue plasminogen activator (alteplase) was approved by the US

26 e: intravenous thrombolysis with tissue-type plasminogen activator and endovascular treatment for pro

27 nents of the fibrinolytic pathway (urokinase plasminogen activator and plasmin) are elaborated in ple

28 rement of nitric oxide, endothelin-1, tissue plasminogen activator and plasminogen activator inhibito

29 D-dimer, plasmin-antiplasmin complex, tissue plasminogen activator and plasminogen activator inhibito

30 t, PAM50, Breast Cancer Index, and urokinase plasminogen activator and plasminogen activator inhibito

31 protein aggregates interact with tissue-type plasminogen activator and plasminogen, via an exposed ly

32 PPXbd enhanced fibrin sensitivity to tissue plasminogen activator and promoted clot retraction durin

33 intrathrombus delivery of recombinant tissue plasminogen activator and thrombus aspiration or macerat

34 lations of PAs such as streptokinase, tissue-plasminogen activator and urokinase have been developed

35 erwent MT with or without intravenous tissue plasminogen activator and were admitted to endovascular-

36 and cell motility via its interactions with plasminogen activators and vitronectin.

37 in >50% of patients treated with tissue-type plasminogen activator), and (5) face-to-face meetings wi

38 hemorepulsive: alpha-2-macroglobulin, tissue plasminogen activator, and metallothionein III.

39 to activate the single-chain urokinase-type plasminogen activator, and the G221A and G221S variants

40 onists, alpha2-macroglobulin and tissue-type plasminogen activator, attenuated expression of inflamma

41 Activated factor XII (FXIIa) has plasminogen activator capacity but its relative contribu

42 lasminogen, which after activation by tissue plasminogen activator cleaved the bound histone.

43 ic protein-1), and formation of PAI-1/tissue plasminogen activator complexes.

44 protein-1 and the formation of PAI-1/tissue plasminogen activator complexes.

45 Intravenous tissue plasminogen activator did not impact outcomes.

46 l approaches such as recombinant tissue-type plasminogen activator, direct thrombin inhibitors, and a

47 Accelerated tPA (tissue-type plasminogen activator) dosing regimens for ultrasound-fa

48 Combined delivery of plasminogen and tissue plasminogen activator during NMP lysed the plugs leading

49 iNPC with enzymatically-inactive tissue-type plasminogen activator (EI-tPA), prior to grafting into a

50 IV recombinant tissue plasminogen activator, endovascular treatment, IV albumi

51 onsisting of 1mg of recombinant human tissue plasminogen activator every 8 hours until clot clearance

52 d increase in cerebral tissue-type/urokinase plasminogen activator expression.

53 cluding alpha2-macroglobulin and tissue-type plasminogen activator, failed to cause LRP1 shedding.

54 Patients were treated with IVT with tissue plasminogen activator followed by MT (IVT and MT group)

55 obal Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries [GUSTO] clas

56 obal Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries moderate or

57 obal Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries moderate/sev

58 obal Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GU

59 novel Ter119-polymeric NP containing tissue plasminogen activator for on-demand targeting of GPA rec

60 investigate the contribution of polyP to the plasminogen activator function of alphaFXIIa.

61 Intravenous tissue plasminogen activator has been a cornerstone for treatme

62 March 31, 2015 and who received tissue-type plasminogen activator in the emergency department at 15

63 atalytic and thrombolytic activity of tissue plasminogen activator in vitro and ex vivo.

64 efficacy of alteplase, a recombinant tissue plasminogen activator, in combination with minimally inv

65 ain neuroprotection and inhibition of tissue plasminogen activator-induced brain hemorrhages.

66 neuroprotective agent if given after tissue plasminogen activator-induced reperfusion.

67 raischemic helium at 75 vol% inhibits tissue plasminogen activator-induced thrombolysis and subsequen

68 after ischemia, in order not to block tissue plasminogen activator-induced thrombolysis and to obtain

69 the risk of inhibiting the benefit of tissue plasminogen activator-induced thrombolysis; and 2) could

70 hesion molecules, fibrinogen-like protein 2, plasminogen activator inhibitor (PAI)-1), secretion of p

71 n 2, tissue plasminogen activator (tPA), and plasminogen activator inhibitor (PAI)-1.

72 ) (by confocal microscopy), plasma levels of plasminogen activator inhibitor (PAI-1), and factor XIII

73 inogen activator, alpha2-antiplasmin, active plasminogen activator inhibitor (PAI-1), and fibrin form

74 chemotactic protein-1 (CCL2) (MCP-1), tissue plasminogen activator inhibitor (PAI-1), and regulated o

75 connective tissue growth factor (CTGF), and plasminogen activator inhibitor (PAI-1).

76 D-dimer, tissue plasminogen activator (tPA), plasminogen activator inhibitor 1 (PAI-1) and platelets.

77 The concentration of the main TPA inhibitor plasminogen activator inhibitor 1 (PAI-1) controlled bot

78 Plasminogen activator inhibitor 1 (PAI-1) is a serpin in

79 pathway and augmented tissue factor (TF) and plasminogen activator inhibitor 1 (PAI-1) levels in veno

80 (MS, n = 20; control, n = 10), expression of plasminogen activator inhibitor 1 (PAI-1), a key enzyme

81 D-dimer, tissue plasminogen activator (tPA), plasminogen activator inhibitor 1 (PAI-1), and platelets

82 vator (tPA) and its physiological inhibitor, plasminogen activator inhibitor 1 (PAI-1), in Puumala ha

83 Furthermore, inhibition of plasminogen activator inhibitor 1 (PAI-1), which was the

84 isolated a high-quality DNA aptamer pair for plasminogen activator inhibitor 1 (PAI-1).

85 Plasminogen activator inhibitor 1 (PAI-1/serpinE1) can b

86 led to upregulate the fibrinolysis inhibitor plasminogen activator inhibitor 1 (Serpine1, also known

87 protein M130, Fatty acid binding protein 4, Plasminogen activator inhibitor 1 and Insulin-like growt

88 Increased activated plasminogen activator inhibitor 1 had a strong associati

89 king BDNF maturation in the hippocampus with plasminogen activator inhibitor 1 hinders the persistenc

90 s and levels of the coagulation intermediary plasminogen activator inhibitor 1 in three mouse models

91 asminogen activators, a relatively decreased plasminogen activator inhibitor 1, and decreased levels

92 r slows down matrix degradation by increased plasminogen activator inhibitor 1.

93 ptor annexin 2A as well as downregulation of plasminogen activator inhibitor serpine1 in myocardium a

94 Recently it has been demonstrated that plasminogen activator inhibitor serpins promote brain me

95 complex, plasmin-alpha2-antiplasmin complex, plasminogen activator inhibitor type 1 [PAI-1], D-dimer,

96 dex, and urokinase plasminogen activator and plasminogen activator inhibitor type 1 in specific subgr

97 SerpinB2 (plasminogen activator inhibitor type 2) is constitutivel

98 Increased levels of plasminogen activator inhibitor type I (PAI-1) have been

99 Plasminogen activator inhibitor type-1 (PAI-1) is a seri

100 Plasminogen activator inhibitor type-1 (PAI-1; encoded b

101 ones emerging (collagen-I, thrombospondin-I, plasminogen activator inhibitor, MMP1, 9, ADAMTS4, TIMP1

102 in complex, tissue plasminogen activator and plasminogen activator inhibitor-1 (markers for fibrinoly

103 Higher plasminogen activator inhibitor-1 (p = 0.002), E-selecti

104 Similarly, higher plasminogen activator inhibitor-1 (p = 0.007) and S100B

105 l transition (EMT), TNBC cells could produce plasminogen activator inhibitor-1 (PAI-1) and stimulate

106 ze the binding interfaces of urokinase (uPA):plasminogen activator inhibitor-1 (PAI-1) and uPA:plasmi

107 Basal expression of plasminogen activator inhibitor-1 (PAI-1) in human and m

108 en activator (uPA), its receptor (uPAR), and plasminogen activator inhibitor-1 (PAI-1) into the early

109 Plasminogen activator inhibitor-1 (PAI-1) is a serine pr

110 Plasminogen activator inhibitor-1 (PAI-1) is known to pr

111 Plasminogen activator inhibitor-1 (PAI-1) is the key end

112 Plasminogen activator inhibitor-1 (PAI-1) is the main in

113 iation of a gain-of-function polymorphism in plasminogen activator inhibitor-1 (PAI-1) with airway ob

114 t gene SERPINE1 that is encoding the protein plasminogen activator inhibitor-1 (PAI-1), an establishe

115 NADPH oxidases (NOXs), and fibrotic markers, plasminogen activator inhibitor-1 (PAI-1), and fibronect

116 VEGF, plasminogen activator inhibitor-1 (PAI-1), and pigment e

117 nase-9 (MMP-9), tumor necrosis factor-alpha, plasminogen activator inhibitor-1 (PAI-1), and urinary o

118 factor receptor (EGFR), p53] and subsequent plasminogen activator inhibitor-1 (PAI-1), connective ti

119 In infected mice that overexpress plasminogen activator inhibitor-1 (PAI-1), S. aureusclfA

120 leomycin failed to induce miR-34a in p53- or plasminogen activator inhibitor-1 (PAI-1)-deficient mice

121 tions and is characterized by high levels of plasminogen activator inhibitor-1 (PAI-1).

122 xia-inducible factor-1alpha (HIF-1alpha) and plasminogen activator inhibitor-1 (PAI-1).

123 eral eNOS interactors, including the protein plasminogen activator inhibitor-1 (PAI-1).

124 receptor type 4 (CXCR4) and upregulation of plasminogen activator inhibitor-1 (PAI-1).

125 e agent shields rt-PA against degradation by plasminogen activator inhibitor-1 (PAI-1).

126 l and extracellular matrix remodeling [e.g., plasminogen activator inhibitor-1 (PAI-1; serine proteas

127 Adjusting for S100B did not alter plasminogen activator inhibitor-1 and E-selectin associa

128 with increased alpha-smooth muscle actin and plasminogen activator inhibitor-1 expression.

129 S-1 peptide had increased efficacy in plasminogen activator inhibitor-1 serpin-deficient trans

130 mediated connective tissue growth factor and plasminogen activator inhibitor-1 up-regulation.

131 Falpha, leptin, adiponectin, fibrinogen, and plasminogen activator inhibitor-1 were determined.

132 There was a 51.8% net decrease in PAI-1 (plasminogen activator inhibitor-1), a 12.1% net decrease

133 ines, including migration inhibitory factor, plasminogen activator inhibitor-1, and C-C motif chemoki

134 d2 phosphorylation, normalized expression of plasminogen activator inhibitor-1, and mitigated PH and

135 pression of interleukin-6, thrombospondin-1, plasminogen activator inhibitor-1, and tissue factor, wh

136 ded natriuretic peptides, cardiac troponins, plasminogen activator inhibitor-1, D-dimer, fibrinogen,

137 We measured plasma concentrations of plasminogen activator inhibitor-1, E-selectin, and angio

138 (+/+) mice contained plasminogen activators, plasminogen activator inhibitor-1, plasminogen, and alph

139 dothelin-1, tissue plasminogen activator and plasminogen activator inhibitor-1, was depressed by expo

140 ependent connective tissue growth factor and plasminogen activator inhibitor-1-induced proliferative

141 or pathway inhibitor, fibrinogen-like 1, and plasminogen activator inhibitor-1.

142 e TSP-1 and decrease VEGF by reducing PAI-1 (plasminogen activator inhibitor-1/SERPINE1) levels.

143 ntal vascular-endothelial function [ratio of plasminogen-activator inhibitor (PAI) 1 to PAI-2 and mea

144 It is well-established that complexes of plasminogen-activator inhibitor 1 (PAI-1) with its targe

145 Plasminogen activator inhibitors (PAIs) 1 and 2 were als

146 tor and histidine-rich glycoprotein, but not plasminogen activator inhibitors 1 and 2.

147 After intravenous tissue plasminogen activator, intra-arterial mechanical thrombe

148 ute ischemic stroke treated with tissue-type plasminogen activator is associated with improved outcom

149 Urokinase (uPA, urinary plasminogen activator) is a serine protease belonging to

150 Intravenous rt-PA (recombinant tissue-type plasminogen activator) is effective in improving outcome

151 Although intravenous tissue plasminogen activator (IV-rtPA) was approved nearly 2 de

152 inst the use of intravenous tPA (tissue-type plasminogen activator; IV tPA) in acute ischemic stroke

153 These patients have low tissue plasminogen activator levels and are not detectable by R

154 erfibrinolytic biomarker profile, low tissue plasminogen activator levels but high plasma levels of S

155 protease thrombin and release the urokinase plasminogen activator loaded into the polymer capsules,

156 mic stroke with intravenous tPA (tissue-type plasminogen activator) may increase the risk of administ

157 where it can be converted to plasmin by host plasminogen activators or by endogenously expressed stap

158 as an inhibitor of urokinase and tissue-type plasminogen activator (PA), PA inhibitor-1 (PAI-1) has a

159 Several plasminogen activators (PAs) have been found effective i

160 s This study demonstrated that the Y. pestis plasminogen activator Pla, a protease that promotes fibr

161 system, and eliminated harmful factors like plasminogen activator (Pla) and murine toxin from the OM

162 te CgA C-terminal cleavage by activating the plasminogen activator/plasmin system.

163 us thrombi from alpha2AP(+/+) mice contained plasminogen activators, plasminogen activator inhibitor-

164 er than 2, grade 2 to 3, high urokinase-type plasminogen activator/plasminogen activator inhibitor-1,

165 old increase in platelet stores of urokinase plasminogen activator (PLAU/uPA); subsequent plasmin-med

166 al thrombus to alteplase (recombinant tissue plasminogen activator), potentially facilitating early r

167 Activating MMP gelatinases with tissue plasminogen activator potentiated cue-induced reinstatem

168 A or glycine) and the serine protease tissue plasminogen activator, previously shown to potentiate NM

169 The plasminogen activator protease (Pla) is a critical Y. pe

170 gression of infection is the activity of the plasminogen activator protease Pla.

171 ential association between soluble urokinase plasminogen activator receptor (suPAR) and incident non-

172 cent studies describe soluble urokinase-type plasminogen activator receptor (suPAR) as a circulating

173 nity, and coagulation, and soluble urokinase plasminogen activator receptor (suPAR) has been identifi

174 The role of the soluble urokinase plasminogen activator receptor (suPAR) in focal segmenta

175 Soluble urokinase plasminogen activator receptor (suPAR) independently pre

176 Systemic soluble urokinase plasminogen activator receptor (suPAR) is a circulating

177 Soluble urokinase plasminogen activator receptor (suPAR) is a signaling gl

178 Soluble urokinase plasminogen activator receptor (suPAR) is an immune-deri

179 e demonstrated that a soluble urokinase-type plasminogen activator receptor (suPAR) plays an essentia

180 We investigated whether soluble urokinase plasminogen activator receptor (suPAR), a marker of immu

181 y) and serum levels of the soluble urokinase plasminogen activator receptor (suPAR), a proposed patho

182 Levels of soluble urokinase plasminogen activator receptor (suPAR), an inflammation

183 Soluble urokinase plasminogen activator receptor (suPAR), lipopolysacchari

184 eloped for rapid detection of urokinase type plasminogen activator receptor (uPAR) - a biomarker for

185 , we used a monoclonal antibody to urokinase plasminogen activator receptor (uPAR) as a therapeutic s

186 nase that upon binding to the urokinase-type plasminogen activator receptor (uPAR) catalyzes the conv

187 tential of PET imaging of the urokinase-type plasminogen activator receptor (uPAR) in glioblastoma.

188 The role of urokinase-type plasminogen activator receptor (uPAR) in kidney physiolo

189 models, the wild type (WT) and the urokinase plasminogen activator receptor (uPAR) KO (uPAR), in an a

190 We identify the urokinase-type plasminogen activator receptor (uPAR)(11) as a cell-surf

191 is capable of recognizing the urokinase-type plasminogen activator receptor (uPAR), a uniquely overex

192 gy: 1) an elevated tumor receptor, urokinase plasminogen activator receptor (UPAR), and 2) the acidic

193 )Ga-NOTA-AE105, targeting the urokinase-type plasminogen activator receptor (uPAR), and Gleason score

194 eted factors, including CD73, urokinase-type plasminogen activator receptor (uPAR), and serum amyloid

195 Transcripts of the urokinase plasminogen activator receptor (uPAR), which facilitates

196 sion levels of alpha5 integrin and urokinase plasminogen activator receptor (uPAR).

197 ntified, we discovered that a urokinase-type plasminogen activator receptor (uPAR)/integrin beta1/Src

198 in the asthma susceptibility gene, urokinase plasminogen activator receptor (uPAR/PLAUR) have been as

199 eraction with a region of the urokinase-type plasminogen activator receptor (uPAR88-92), able to inte

200 x [IGFBP7]), and the soluble urokinase-type plasminogen activator receptor are of diagnostic value f

201 IMP-2] x [IGFBP7] and soluble urokinase-type plasminogen activator receptor are promising biomarker c

202 Sirt6 also reduces urokinase plasminogen activator receptor expression, which is a ke

203 Soluble urokinase-type plasminogen activator receptor levels at inclusion showe

204 s over time and serum soluble urokinase-type plasminogen activator receptor levels once at inclusion

205 Soluble urokinase-type plasminogen activator receptor performed best by using a

206 imicrobial peptides antigen-6/urokinase-type plasminogen activator receptor related protein-1 and bet

207 tudy the ability of suPAR (soluble urokinase plasminogen activator receptor), a potential biomarker o

208 necrosis factor receptor 1), UPAR (urokinase plasminogen activator receptor), IGFBP7 (insulin-like gr

209 phropathy biomarkers, soluble urokinase-type plasminogen activator receptor, suPAR and neutrophil gel

210 an endocytic mechanism governed by urokinase plasminogen activator receptor-associated protein (uPARA

211 The overexpression of urokinase-type plasminogen activator receptors (uPARs) represents an es

212 ion, partly caused by hypoxia induced tissue plasminogen activator release.

213 Intravenous thrombolysis with tissue-type plasminogen activator remains the mainstay of acute stro

214 zed octafluoropropane and recombinant tissue plasminogen activator (rt-PA)-loaded echogenic liposomes

215 ent with intravenous (IV) recombinant tissue plasminogen activator (rtPA) after mild stroke.

216 andidates for intravenous recombinant tissue plasminogen activator (rtPA) because their symptoms are

217 trievers with intravenous recombinant tissue plasminogen activator (rtPA) compared with rtPA alone.

218 As thrombolysis with recombinant tissue plasminogen activator (rtPA) is a standard of care withi

219 ischemic stroke who were treated with tissue plasminogen activator, shorter door-to-needle times were

220 Currently, tissue plasminogen activator (t-PA) is the only approved thromb

221 male C57bl/6 mice, thrombolysis using tissue-plasminogen activator (t-PA) reduced injury and improved

222 dominated by the experience with tissue-type plasminogen activator (t-PA), which proved little better

223 ove current thrombolytic therapy with tissue plasminogen activator (t-PA).

224 or, fatty acid-binding protein 4, and tissue plasminogen activator [t-PA]) as IR biomarkers.

225 interacts with the thrombolytic drug tissue plasminogen activator, the only approved therapy of acut

226 administered before or together with tissue plasminogen activator therapy due to the risk of inhibit

227 i acutely and r-tPA (recombinant tissue-type plasminogen activator) therapy may be required, despite

228 I-1 with low-molecular-weight urokinase-type plasminogen activator to LRP1.

229 be one-directional: from matriptase, through plasminogen activator, to plasminogen.

230 The plasminogen activator tPA was lower in HA-NCI while neur

231 ivities of the fibrinolysis protease, tissue plasminogen activator tPA, without effects on hemostasis

232 f fibrinolysis after recombinant tissue-type plasminogen activator (tPA) administration revealed that

233 endovascular therapy plus intravenous tissue plasminogen activator (tPA) administration versus tPA ad

234 reduction in treatment times for tissue-type plasminogen activator (tPA) administration.

235 mized treatment with intravenous (IV) tissue plasminogen activator (tPA) alone versus IV tPA + endova

236 ulation of 2 fibrinolytic parameters, tissue plasminogen activator (tPA) and its physiological inhibi

237 ofibrinolytic enzymes, urokinase, and tissue plasminogen activator (TPA) as a source for plasmin form

238 ed delivery and controlled release of tissue plasminogen activator (tPA) at the thrombus site.

239 nce-dependent proteolytic activity of tissue plasminogen activator (tPA) becomes restricted in the ad

240 ral activation through a reduction in tissue plasminogen activator (tPA) caused by upregulation of it

241 d recipient WIT along with the use of tissue plasminogen activator (tPA) flush during DCD procurement

242 Earlier administration of intravenous tissue plasminogen activator (tPA) in acute ischemic stroke is

243 Thrombolytic therapy using tissue plasminogen activator (tPA) in acute stroke is associate

244 on-advection model of thrombolysis by tissue plasminogen activator (TPA) in an occluded vessel with a

245 Tissue-type plasminogen activator (tPA) is a major mediator of fibri

246 Intravenous tissue plasminogen activator (tPA) is known to improve outcomes

247 Tissue-type plasminogen activator (tPA) is the major intravascular a

248 rombolytic treatment with recombinant tissue plasminogen activator (tPA) may exacerbate blood-brain b

249 gen and enhances its association with tissue plasminogen activator (tPA) thereby enhancing plasmin pr

250 ue factor, fibrinogen-like protein 2, tissue plasminogen activator (tPA), and plasminogen activator i

251 Emerging evidence suggests that tissue plasminogen activator (tPA), currently the only FDA-appr

252 nd peritoneal fluid concentrations of tissue plasminogen activator (tPA), d-dimer, thrombin-antithrom

253 rin more resistant to fibrinolysis by tissue plasminogen activator (tPA), exacerbating the prothrombo

254 ed partial prothrombin time, D-dimer, tissue plasminogen activator (tPA), plasminogen activator inhib

255 ernational normalized ratio, D-dimer, tissue plasminogen activator (tPA), plasminogen activator inhib

256 Tissue plasminogen activator (tPA), which is reduced in Alzheim

257 use of a fibrinolytic enzyme such as tissue plasminogen activator (tPA).

258 ection of a plasmid encoding for tissue-type plasminogen activator (tPA).

259 which includes the use of intravenous tissue plasminogen activator (tPA).

260 lytic treatment with recombinant tissue-type plasminogen activator (tPA).

261 into the source of intravascular tissue-type plasminogen activator (tPA).

262 o bind fibrinogen D fragment close to tissue plasminogen activator (tPA; residues gamma312-324) and p

263 me exosite used by both tissue and urokinase plasminogen activators (tPA and uPA).

264 ) and had higher rates of intravenous tissue plasminogen activator treatment (174 [74.4%] vs 172 [59.

265 ographic Score (ASPECTS), intravenous tissue plasminogen activator treatment, and time from LKN to ar

266 scores after accounting for tPA (tissue-type plasminogen activator) treatment.

267 njury following activation by urokinase-type plasminogen activator (u-PA; encoded by the PLAU gene).

268 we show that neurons release urokinase-type plasminogen activator (uPA) and astrocytes recruit the u

269 ing the enzymatic activity of urokinase-type plasminogen activator (uPA) and matrix metalloproteinase

270 to analyze the interaction between urokinase plasminogen activator (uPA) and monoclonal uPAR antibody

271 apoptosis with suppression of urokinase-type plasminogen activator (uPA) and the uPA receptor in AECs

272 of the plasminogen activators urokinase-type plasminogen activator (uPA) and tissue plasminogen activ

273 diac fibrosis by inactivating urokinase-type plasminogen activator (uPA) and ultimately plasmin (Pm)

274 upregulated the expression of urokinase-type plasminogen activator (uPA) and/or matrix metalloprotein

275 Urokinase plasminogen activator (uPA) converts plasminogen to plas

276 EGFR TKIs, elevated expression of urokinase plasminogen activator (uPA) drives signaling through the

277 Urokinase-type plasminogen activator (uPA) is a serine proteinase that

278 Urokinase-type plasminogen activator (uPA) is a serine proteinase that,

279 Urokinase-type plasminogen activator (uPA) is a serine proteinase that,

280 elet (PLT) alpha granule-delivered urokinase plasminogen activator (uPA) is highly effective in preve

281 Genetic absence of the urokinase-type plasminogen activator (uPA) reduces arthritis progressio

282 Urokinase-type plasminogen activator (uPA) regulates angiogenesis and v

283 trypsin-like serine protease, urokinase-type plasminogen activator (uPA), is central in tissue remode

284 tment increased endocytosis of the urokinase plasminogen activator (uPA), its receptor (uPAR), and pl

285 chitosan, targeting acidic pH, and urokinase plasminogen activator (UPA), targeting UPAR.

286 ary biochemical target of SerpinB2-urokinase plasminogen activator (uPA).

287 d angiomyolipomas overexpress urokinase-type plasminogen activator (uPA).

288 is due to the effects of t-PA and urokinase plasminogen activator (uPA).

289 n consensus cleavage motif of urokinase-type plasminogen activator (uPA).

290 olytic cascade of cathepsin B/urokinase-type plasminogen activator (uPA)/matrix metalloproteinase-2 (

291 bitor 1 (PAI-1) is a serpin inhibitor of the plasminogen activators urokinase-type plasminogen activa

292 ty and efficacy of leukocyte antigen, PLAUR (plasminogen activator, urokinase receptor) domain-contai

293 te Ischemic Stroke network: tPA (tissue-type plasminogen activator) use, complications related to tPA

294 total dose of r-tPA (recombinant tissue-type plasminogen activator) was 14 mgs in bilateral PE and 12

295 uPA (urokinase-type plasminogen activator) was related to systolic blood pre

296 ory increase in expression of urokinase-type plasminogen activator, which activates uPAR-dependent ce

297 -type plasminogen activator (uPA) and tissue plasminogen activator, which binds tightly to the cleara

298 ix patients (4%) received intravenous tissue plasminogen activator without complications.

299 d patients suggested that intravenous tissue plasminogen activator would be delayed by 12 minutes, bu

300 e radius from onset, then intravenous tissue plasminogen activator would be delayed by 7 minutes and